Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives Average Recommendation of "Moderate Buy" from Brokerages

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the nine brokerages that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $19.67.

TEVA has been the topic of a number of recent research reports. JPMorgan Chase & Co. upped their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a "neutral" rating in a research report on Monday, October 21st. Barclays increased their target price on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an "overweight" rating in a report on Wednesday, October 23rd. StockNews.com raised Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research report on Thursday, October 17th. UBS Group upped their target price on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a "buy" rating in a report on Tuesday, September 3rd. Finally, Argus raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating and set a $20.00 price target for the company in a research report on Wednesday, July 10th.

Teva Pharmaceutical Industries Trading Up 0.8 %

Shares of NYSE:TEVA traded up $0.16 during mid-day trading on Wednesday, reaching $18.59. 6,343,361 shares of the company were exchanged, compared to its average volume of 9,307,149. Teva Pharmaceutical Industries has a 1 year low of $8.42 and a 1 year high of $19.08. The company has a debt-to-equity ratio of 2.52, a current ratio of 0.89 and a quick ratio of 0.59. The firm's 50-day simple moving average is $18.02 and its 200 day simple moving average is $16.87. The firm has a market cap of $21.05 billion, a price-to-earnings ratio of -45.33, a P/E/G ratio of 1.29 and a beta of 0.88.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.03. The firm had revenue of $4.16 billion for the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. Equities research analysts forecast that Teva Pharmaceutical Industries will post 2.33 EPS for the current year.

Insider Activity

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 24,537 shares of the firm's stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $17.25, for a total transaction of $423,263.25. Following the sale, the insider now directly owns 45,060 shares of the company's stock, valued at $777,285. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.55% of the company's stock.

Institutional Trading of Teva Pharmaceutical Industries

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TEVA. Renaissance Technologies LLC raised its position in shares of Teva Pharmaceutical Industries by 13.4% in the 2nd quarter. Renaissance Technologies LLC now owns 8,728,563 shares of the company's stock worth $141,839,000 after buying an additional 1,031,400 shares during the period. Maple Rock Capital Partners Inc. increased its stake in Teva Pharmaceutical Industries by 68.3% during the first quarter. Maple Rock Capital Partners Inc. now owns 4,363,401 shares of the company's stock worth $61,568,000 after acquiring an additional 1,770,000 shares during the last quarter. Truist Financial Corp lifted its stake in shares of Teva Pharmaceutical Industries by 7.0% in the 2nd quarter. Truist Financial Corp now owns 3,885,251 shares of the company's stock valued at $63,135,000 after purchasing an additional 254,483 shares in the last quarter. National Pension Service lifted its stake in shares of Teva Pharmaceutical Industries by 107.3% in the 3rd quarter. National Pension Service now owns 3,170,640 shares of the company's stock valued at $57,135,000 after purchasing an additional 1,640,940 shares in the last quarter. Finally, Iron Triangle Partners LP grew its holdings in shares of Teva Pharmaceutical Industries by 113.1% during the 1st quarter. Iron Triangle Partners LP now owns 2,769,864 shares of the company's stock worth $39,083,000 after purchasing an additional 1,469,864 shares during the period. Hedge funds and other institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.